Suppr超能文献

肝纤维化中基质蛋白的降解

Degradation of matrix proteins in liver fibrosis.

作者信息

Arthur M J

机构信息

University Medicine, University of Southampton, UK.

出版信息

Pathol Res Pract. 1994 Oct;190(9-10):825-33. doi: 10.1016/S0344-0338(11)80985-4.

Abstract

Hepatic fibrosis occurs as a consequence of net accumulation of matrix proteins (particularly collagen types I and III) in liver. Current concepts of the pathogenesis of liver fibrosis place major emphasis on the activation of hepatic lipocytes (fat-storing or Ito cells) to a myofibroblast-like phenotype with a consequent increase in their synthesis of matrix proteins. While this is an important factor, there is increasing evidence to indicate that liver fibrosis is a dynamic pathologic process in which altered matrix degradation may also play a significant role. Extracellular degradation of matrix proteins is regulated by a family of enzymes called the matrix metalloproteinases, which is subdivided into three groups; collagenases which degrade interstitial collagens (types I, II and III), type IV collagenases/gelatinases which degrade basement membrane (type IV) collagen and gelatins and stromelysins which degrade a broad range of substrates including proteoglycans, laminin, gelatins and fibronectin. The extracellular activity of these enzymes is regulated by several mechanisms which include alterations in gene transcription and proenzyme synthesis, cleavage of secreted proenzymes to active forms, and specific inhibition of activated forms by tissue inhibitor(s) of metalloproteinases (TIMPs). In liver, current evidence indicates that activated hepatic lipocytes and Kupffer cells play a central role in synthesis of matrix metalloproteinases. Under defined conditions they synthesize interstitial collagenase, 72 kDa and 95 kDa type IV collagenase/gelatinase and possibly stromelysin. Moreover, lipocytes also contribute to regulation of the extracellular activity of these enzymes by secretion of TIMP-1 and alpha 2-macroglobulin.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

肝纤维化是肝脏中基质蛋白(特别是I型和III型胶原)净积累的结果。目前关于肝纤维化发病机制的概念主要强调肝脂肪细胞(贮脂细胞或伊托细胞)激活为成肌纤维细胞样表型,进而导致其基质蛋白合成增加。虽然这是一个重要因素,但越来越多的证据表明,肝纤维化是一个动态病理过程,其中基质降解改变也可能起重要作用。基质蛋白的细胞外降解由一类称为基质金属蛋白酶的酶调节,该酶分为三组;降解间质胶原(I型、II型和III型)的胶原酶,降解基底膜(IV型)胶原和明胶的IV型胶原酶/明胶酶,以及降解包括蛋白聚糖、层粘连蛋白、明胶和纤连蛋白在内的多种底物的基质溶解素。这些酶的细胞外活性受多种机制调节,包括基因转录和酶原合成的改变、分泌的酶原切割为活性形式,以及金属蛋白酶组织抑制剂(TIMPs)对活性形式的特异性抑制。在肝脏中,目前的证据表明,激活的肝脂肪细胞和库普弗细胞在基质金属蛋白酶的合成中起核心作用。在特定条件下,它们合成间质胶原酶、72 kDa和95 kDa IV型胶原酶/明胶酶,可能还合成基质溶解素。此外,脂肪细胞还通过分泌TIMP-1和α2-巨球蛋白参与这些酶细胞外活性的调节。(摘要截断于250字)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验